中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
1期
21-22
,共2页
谢昌辉%李秀江%朱琳%马志海%欧阳思
謝昌輝%李秀江%硃琳%馬誌海%歐暘思
사창휘%리수강%주림%마지해%구양사
肺栓塞%肺灌注%放射性同位素%危险性评估
肺栓塞%肺灌註%放射性同位素%危險性評估
폐전새%폐관주%방사성동위소%위험성평고
Pulmonary embolism%Pulmonary perfusion%Radioisotopes%Risk assessment
目的 探讨肺栓塞(PE)患者肺灌注缺损百分数测定(PPDS％)的临床价值.方法 回顾36例临床确诊的PE患者资料,依据PPDS％值(低危PPDS％＜ 30％、中危30％≤PPDS％＜ 50％、高危PPDS％≥50％)对PE进行危险分层,比较低危、中危、高危PE的PPDS％及其临床不良事件发生率,对比治疗前后的PPDS％变化.结果 36例患者依据PPDS％值分级为低危15例、中危13例、高危8例,依据2008欧洲心脏病学会(ESC)指南分级为低危16例、中危12例、高危8例,两者的分级一致率为94.4％(34/36),其中高危患者的分级一致率为100.0％(8/8).PE治疗前的PPDS％为(46.2±4.6)％,明显高于治疗后[(31.6±1.8)％](t =17.38,P＜0.01)；低危、中危、高危PE的PPDS％分别为(25.9±3.9)％、(45.6±4.3)％、(58.4±4.9)％(t=6.18,P＜0.01).低危、中危、高危PE分别有1例(6.5％)、3例(23.0％)、5例(62.5％)发生临床不良事件,差异有统计学意义(x2 =8.71,P＜0.05).结论 PPDS％可作为PE分级诊断、预后判断及疗效观察的重要参考指标.
目的 探討肺栓塞(PE)患者肺灌註缺損百分數測定(PPDS％)的臨床價值.方法 迴顧36例臨床確診的PE患者資料,依據PPDS％值(低危PPDS％＜ 30％、中危30％≤PPDS％＜ 50％、高危PPDS％≥50％)對PE進行危險分層,比較低危、中危、高危PE的PPDS％及其臨床不良事件髮生率,對比治療前後的PPDS％變化.結果 36例患者依據PPDS％值分級為低危15例、中危13例、高危8例,依據2008歐洲心髒病學會(ESC)指南分級為低危16例、中危12例、高危8例,兩者的分級一緻率為94.4％(34/36),其中高危患者的分級一緻率為100.0％(8/8).PE治療前的PPDS％為(46.2±4.6)％,明顯高于治療後[(31.6±1.8)％](t =17.38,P＜0.01)；低危、中危、高危PE的PPDS％分彆為(25.9±3.9)％、(45.6±4.3)％、(58.4±4.9)％(t=6.18,P＜0.01).低危、中危、高危PE分彆有1例(6.5％)、3例(23.0％)、5例(62.5％)髮生臨床不良事件,差異有統計學意義(x2 =8.71,P＜0.05).結論 PPDS％可作為PE分級診斷、預後判斷及療效觀察的重要參攷指標.
목적 탐토폐전새(PE)환자폐관주결손백분수측정(PPDS％)적림상개치.방법 회고36례림상학진적PE환자자료,의거PPDS％치(저위PPDS％＜ 30％、중위30％≤PPDS％＜ 50％、고위PPDS％≥50％)대PE진행위험분층,비교저위、중위、고위PE적PPDS％급기림상불량사건발생솔,대비치료전후적PPDS％변화.결과 36례환자의거PPDS％치분급위저위15례、중위13례、고위8례,의거2008구주심장병학회(ESC)지남분급위저위16례、중위12례、고위8례,량자적분급일치솔위94.4％(34/36),기중고위환자적분급일치솔위100.0％(8/8).PE치료전적PPDS％위(46.2±4.6)％,명현고우치료후[(31.6±1.8)％](t =17.38,P＜0.01)；저위、중위、고위PE적PPDS％분별위(25.9±3.9)％、(45.6±4.3)％、(58.4±4.9)％(t=6.18,P＜0.01).저위、중위、고위PE분별유1례(6.5％)、3례(23.0％)、5례(62.5％)발생림상불량사건,차이유통계학의의(x2 =8.71,P＜0.05).결론 PPDS％가작위PE분급진단、예후판단급료효관찰적중요삼고지표.
Objective To investigate the clinical value of the decfion of percentage of pulmonary perfusion defect score (PPDS％) in patients with pulmonary embolism (PE).Methods A retrospective study was carried out on PPDs％ data of patients(n =36) with clinical confirmed PE.The patients were divided into three levels:low (PPDS％ ＜30％),medial (30％ ≤PPDS％ ＜50％) and high (PPDS％ ≥50％) risk groups,according to the standard of PPDs％ diagnosis.the PPDS％ and the incidence rate of the clinical adverse events were compared in mild,moderate and severe risk PE.The therapeutic results were compared with the PPDS％ changes.Results The mild,moderate and severe risk patients with PE were 15 cases,13 cases and 8 cases respectively,according to the standard of PPDS％ diagnosis.16 cases,12 cases and 8 cases respectively,according to the standard of 2008 ESC APE diagnosis and treatment guidelines.The uniform rate was 94.4％ for two methods,the uniform rate was 100.0％ in which high risk of PE.The PPDS％ of PE was (46.2 ± 4.6) ％ before treatment.The data was significantly higher than that post treatment (31.6％ ± 1.8％) (t =17.38,P ＜ 0.01).The scores of low,medial and high risk patients were (25.9 ± 3.9) ％,(45.6 ± 4.3) ％ and (58.4 ± 4.9) ％ (t =6.18,P ＜ 0.01),respectively.The mild,moderate and severe risk PE according to the PPDS％ standard with clinical adverse events for were 1 cases (6.5％),3 cases (23.0％) and 5 cases (62.5 ％) respectively,with a significant difference (x2 =8.71,P ＜ 0.05).Conclusion PPDS％ could be used as an important reference index for risk stratification of diagnosis,evaluating therapeutic efficiency and predicting the prognosis in patients with PE.
